Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$63.34M, compared with -$68.33M a year earlier. Trailing-twelve-month EBITDA was -$210.87M.

Context

  • EBITDA amounted to 149.6% of revenue in FY2025, down 63.7 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -$194.03M (+23.8%) for the fiscal year ending Dec 2026, a slowdown from the +47.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$63.34M-81.7% QoQ
Last fiscal yearDec 2025
-$254.61M+47.4% YoY
LTMMar 2026
-$210.87M+45.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.3%+2.5%-4.8 pp
1 year+47.4%+23.8%-23.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(254.61M) USD
Year-over-year change
+47.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.6% is the 3rd highest of 10, against a peer median of -14.0%.
  • EBITDA amounts to 149.2% of revenue for DNA, versus a peer median of 88.8%.
DNA Competitors
EBITDA for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$55.57M USD+77.9%—26.6%
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M USD+32.5%—120.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M USD-14.0%——
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M USD-85.2%——
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$185.11M USD+47.9%—48.8%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$210.87M USD+45.6%—149.2%
ARVNArvinas, Inc.LTM Mar 2026-$216.5M USD-437.2%—242.2%
REPLReplimune Group, Inc.LTM Dec 2025-$311.38M USD-33.2%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
Peer median (excluding DNA) —-14.0%—88.8%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.